AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05097612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiftSuit Exoskeleton (low support level)
Description: The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
Study NCT05097612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiftSuit Exoskeleton (medium support level)
Description: The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
Study NCT05097612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiftSuit Exoskeleton (high support level)
Description: The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
Study NCT05465941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection
Study NCT05237219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive heating
Description: Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
Study NCT05237219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoneutral
Description: Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
Study NCT05036590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.
Study NCT05036590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.
Study NCT06645431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water Intake
Description: Previous studies have not observed blood glucose with adequate vs. low water intake in a free-living situation. The use of continuous glucose monitors allows this.
Study NCT06191445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Landmark Technique
Description: The investigator will perform spinal anesthesia using the conventional landmark technique.
Study NCT06191445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Assisted Technique
Description: The investigator will perform spinal anesthesia using the ultrasound assisted technique.
Study NCT06191445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real-Time Ultrasound Guided Technique
Description: The investigator will perform spinal anesthesia using the real-time ultrasound-guided technique.
Study NCT06263101 — intervention group
Intervention type: OTHER
Intervention: Biochemical testing of abdominal drainage fluid
Description: Drainage fluid was collected from patients on the first and third postoperative days to test the levels of three biochemical tests (albumin, lactate dehydrogenase \[LDH\], adenosine deaminase \[ADA\]).
Study NCT06263101 — intervention group
Intervention type: OTHER
Intervention: Cytological examination of abdominal drainage fluid
Description: Cytological examination of abdominal drainage fluid on the first postoperative day and the third postoperative day, calculation of neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), prognostic nutritional index (PNI)
Study NCT06263101 — intervention group
Intervention type: OTHER
Intervention: Peripheral blood cytology tests
Description: Peripheral blood cytology tests on the first postoperative day and the third postoperative day, calculation of Neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet lymphocyte ratio (PLR), systemic immunoinflammatory index (SII)
Study NCT04765982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Checking diabetes development in follow up at 3 month
Description: An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
Study NCT04765982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Checking diabetes development in follow up at 3 month
Description: An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
Study NCT04861610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mindfulness based program
Description: An intervention promotes the acceptance and emotion regulation in caregiving for frail older adults
Study NCT04861610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: An intervention promotes the coping and problem solving in caregiving for the frail older adults
Study NCT05924334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reiki
Description: Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average.
Study NCT05924334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT06109324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation of the upper limb
Description: Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions.
Study NCT06109324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation of the upper limb
Description: Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions.
Study NCT04618276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: PDT with two different photosensitizers
Study NCT05540860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 1
Description: Sevasemten is administered orally once per day
Study NCT05540860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 2
Description: Sevasemten is administered orally once per day
Study NCT05012176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in EFT
Study NCT05012176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Participate in ERT
Study NCT05012176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05012176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05012176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05012176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04965727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device implantation
Description: The intervention involves the insertion of lead electrodes (Medtronic SenSight Directional Lead) in the right and left lateral hypothalamus through craniotomy and an implantable pulse generator (Medtronic Model B35200 Percept™ PC) in the upper part of the pectoralis major (under the clavicle).
Study NCT02587884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Patients will treated by TACE in 4 or 8 weeks after operation.
Study NCT05540860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 3
Description: Sevasemten is administered orally once per day
Study NCT05540860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 4
Description: Sevasemten is administered orally once per day
Study NCT05540860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 5
Description: Sevasemten is administered orally once per day
Study NCT05540860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day
Study NCT05963308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds
Description: The group intervention (approximately 5 participants per group, 8 groups) is facilitated by two clinicians and consists of 8 sessions (one per week for 8 weeks), with each session focusing on a specific aspect of the return-to-work process from a cognitive-behavioral perspective:~Week1: Coping with work stress at work W2 and W3: Recognizing and modifying my dysfunctional beliefs linked to work W4: Overcoming obstacles linked to work functioning and maintaining work W5: To put in place needed work accommodations with the support of the immediate supervisor W6: My strengths and competencies related to work W7: Accepting criticism and asserting myself appropriately W7: My strengths and related skills W8: My best coping strategies for work Both intervention and control participants receive their standard individualized care from their clinician. However, for the experimental participants, the Healthy Minds intervention is an added component to their regular care.
Study NCT05270486 — intervention group
Intervention type: PROCEDURE
Intervention: Electromagnetic navigation system
Description: The aim of this study is to assess the safety and efficacy of TELD assisted by electromagnetic navigation for treating lumbar disc herniation (LDH).
Study NCT05365035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given by Vein (IV)
Study NCT05365035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given under the skin; subcutaneous injection (SQ)
Study NCT05365035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT05365035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by IV or subcutaneous injection (SQ)
Study NCT06026631 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lipidomic analysis for breast cancer patients
Description: Lipidomic analysis for breast cancer patients
Study NCT04877366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: Sprinkled Format REDUCOSE.
Description: 2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
Study NCT04877366 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference control
Description: A placebo matching to the test product will be used as control
Study NCT04877366 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active comparator
Description: Acarbose 100 mg tablet (provided in open-label format)
Study NCT05556616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.
Study NCT05556616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules orally.
Study NCT05556616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib injection subcutaneously.
Study NCT05556616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib intravenous infusion.
Study NCT05556616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab injection subcutaneously.
Study NCT05556616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide capsules orally.
Study NCT04925388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rapid molecular diagnosis
Description: peritoneal samples will be analysed using Unyvero IAI test
Study NCT04925388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional method analysis
Description: peritoneal samples will be analysed using conventional method
Study NCT04925388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional method analysis
Description: peritoneal samples will be analysed using conventional method
Study NCT05727436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dentoblis
Description: Dissolve the tablets in the mouth once a day for 4 weeks
Study NCT05118386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSM01
Description: Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 600 mg IM
Study NCT05118386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM
Study NCT06026631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipidomic analysis for breast cancer patients
Description: Lipidomic analysis for breast cancer patients
Study NCT04705766 — intervention group
Intervention type: OTHER
Intervention: Urine Collection
Description: A urine collection kit will be mailed to subjects' residence at 3 different timepoints over the course of 1 year to be returned to study team, upon which KIT score and other biomarkers will be assessed as outlined in the study design.
Study NCT04668274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg resveratrol as JOTROL
Description: Low (first) dose of single ascending dose study
Study NCT04668274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol as JOTROL
Description: Second (intermediate) dose of single ascending dose study
Study NCT04668274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 mg resveratrol as JOTROL
Description: Third (highest) dose of single ascending dose study
Study NCT05414799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: figure eight vision exercise
Description: figure 8 vision exercise is performed in sitting position focus on a point 10 feet away, trace an imaginary horizontally figure 8 with eyes. keep tracing figure eight.
Study NCT05414799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: figure eight vision exercise
Description: figure 8 vision exercise is performed in sitting position focus on a point 10 feet away, trace an imaginary horizontally figure 8 with eyes. keep tracing figure eight.
Study NCT05414799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chin nodding
Description: chin nodding performed in sitting for keeping head placed straight over spine, place finger on chin and tuck-in the chin while head straight back until a stretch is felt at base of head.
Study NCT04668274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol as JOTROL administered to assess influence of food
Description: 500 mg resveratrol as JOTROL administered to assess influence of food
Study NCT05414799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neck stretching
Description: trapezius : neck flexion with opposite side bending and same side rotation for both sides.~sternocleidomastoid : neck extension with opposite side bending and same side rotation for both sides.
Study NCT05450211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)
Description: A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in group SFI.
Study NCT05450211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: Patient-controlled analgesia will be used for pain control after surgery in both groups.
Study NCT05727436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dissolve the tablets in the mouth once a day for 4 weeks
Study NCT04372953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive End-Expiratory Pressure (PEEP)
Description: PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV).
Study NCT04372953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive End-Expiratory Pressure (PEEP)
Description: PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV).